News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Melanoma’ clear

  • Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.

Tags: Melanoma, Immunotherapy

  • Researchers reported survival of patients with advanced melanoma was improved when they received an immune stimulant along with a checkpoint blocker immunotherapy drug. The combination also resulted in fewer serious side effects compared with patients who got only the immunotherapy drug, ipilimumab.

Tags: Melanoma, Immunotherapy

  • F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.

Tags: Melanoma, Immunotherapy

  • Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.

Tags: Melanoma, Immunotherapy

  • Dana-Farber researchers found that in patients with advanced melanoma using the immunotherapy ipilimumab, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in the blood was associated with a poorer response, suggesting that combining immunotherapy with VEGF inhibitors may be a potential option for these patients.

Tags: Melanoma, SkinCancer, Immunotherapy

  • Dana-Farber researchers found that combining the immune stimulator GM-CSF with the antibody drug ipilimumab prolonged survival in patients with metastatic melanoma and reduced the incidence of the most serious side effects.

Tags: Melanoma

  • Dana-Farber and Broad Institute researchers have identified two mutations that collectively occur in 71 percent of malignant melanoma tumors. These highly "recurrent" mutations may be the most common mutations in melanoma cells found to date.

Tags: Genomics, Melanoma

  • Dana-Farber researchers are studying melanoma tumors' microenvironments to better understand how some melanoma continue to grow and survive despite the presence of anti-cancer drugs.

Tags: BasicResearch, Genomics, Melanoma

  • A clinical trial for advanced melanoma caused growths to recede or stabilize in half of the participants by blocking a protein interaction that prevents T cells from attacking cancerous cells, reports lead author Stephen Hodi, MD.

Tags: ImmuneSystem, Melanoma

  • Scientists from Dana-Farber and the Broad Institute have sequenced 25 melanoma tumors and confirmed the long-held suspicion that chronic sun exposure plays a role in skin cancer.

Tags: Genomics, Melanoma

Showing 1-10 of 24 items